David Ricks, Chair and CEO of Eli Lilly, joins Scott to discuss the rise of GLP-1 drugs, the future of obesity treatment, and why America's healthcare system is facing a crisis of trust. They explore healthcare costs, addiction, unregulated peptides, pharmaceutical innovation, and the role AI could play in the next generation of drug discovery. Want to listen to this and other episodes ad-free? You can, if you subscribe at profgmedia.com. Learn more about your ad choices. Visit podcastchoices.com/adchoices
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from The Prof G Pod with Scott Galloway
The Week: AI, GLP-1s, and Scott's Iran War Reversal
Is Energy the Next Big Trade? + How to Actually Tax Billionaires
China Decode: Can China Challenge Nvidia’s Dominance?
Is AI Coming for Your Boss? + How To Become a Better Storyteller
Get summaries like this every morning.
Free AI-powered recaps of The Prof G Pod with Scott Galloway and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.